A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit <a rel="external noopener" href="https://core.ac.uk/download/pdf/82738011.pdf">the original URL</a>. The file type is <code>application/pdf</code>.
<i title="Elsevier BV">
<a target="_blank" rel="noopener" href="https://fatcat.wiki/container/tp6msqxeyjdxpo4i4ouy6t32w4" style="color: black;">Radiotherapy and Oncology</a>
Results: Dose-volume-histogram data for the standard (solid) and escalated (dashed) arms for one patient is presented (Figure 1 ). Centres entering the NARLAL2 trial must successfully pass a workshop evaluation on delineation, PET determination, treatment planning, and IGRT strategy. Additionally, all participating centres should expect to enrol ≥5 patients/year, use 4D-CT and PET, inverse treatment planning, daily online match on soft tissue, and have an adaptive treatment strategy. Planning<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1016/s0167-8140(16)33185-1">doi:10.1016/s0167-8140(16)33185-1</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/bc4244ad4fhkpkkhydatsm5pxy">fatcat:bc4244ad4fhkpkkhydatsm5pxy</a> </span>
more »... d treatment of the initial two patients within each centre are thoroughly investigated by a small QA work group consisting of 2 clinical oncologists and 4 physicists. Furthermore, every six month each centre will be visited by an external oncologist in order to ensure that guidelines are still followed throughout the duration of the trial. Conclusion: The NARLAL2 trial started patient accrual in January 2015 based on this extensive QA work. Purpose or Objective: In the DBCG HYPO trial a number of radiation therapy (RT) parameters were prospectively determined for each individual treatment plan. These parameters were reported to a database and analyzed to determine the plan quality in the trial. Material and Methods: Patients (pts) for breast-only RT after surgery for early node-negative breast cancer from 8 RT centre in 3 countries were included in the trial between May 2009 and March 2014. They were randomized to either 40 Gy/15 fx or 50 Gy/25 fx. A number of plan-quality parameters such as doses to CTV-breast and organs at risk were determined for each plan. The use of respiratory gating during treatment was reported. Definitions on compliance to protocol guidelines, as well as minor and major deviations (Table 1) were agreed upon before trial start. After closing the trial, the QA parameters were analyzed and scored.
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190318103233/https://core.ac.uk/download/pdf/82738011.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/58/6d/586d03fd1153238b15abf72f1634d8be6ee4c038.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1016/s0167-8140(16)33185-1"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="unlock alternate icon" style="background-color: #fb971f;"></i> elsevier.com </button> </a>